mani
countri
face
uphil
battl
combat
spread
infecti
diseas
two
halv
human
immun
system
divid
innat
adapt
immun
system
former
less
specif
suppos
latter
innat
immun
first
line
defenc
infect
cast
wide
protect
net
foreign
protein
work
hors
innat
immun
respons
mostli
present
onset
infect
diseas
specif
cellular
molecular
compon
associ
innat
immun
respons
like
lysozym
interferon
complement
tolllik
receptor
function
mean
recogn
differ
class
molecul
uniqu
frequent
encount
pathogen
hand
adapt
immun
system
highli
specif
capabl
recogn
specif
foreign
microorgan
antigen
select
elimin
bodi
differ
innat
immun
respons
mainli
reaction
toward
specif
challeng
adapt
immun
respons
showcas
four
critic
attribut
allow
effect
respons
infect
show
high
antigen
specif
requir
gener
elev
divers
recognit
entiti
exhibit
immunolog
memori
allow
heighten
respons
toward
subsequ
encount
pathogen
permit
recognit
self
nonself
elev
risk
inappropri
respons
selfcompon
importantli
one
note
innat
adapt
immun
respons
actual
function
sync
cooper
manner
instig
effici
combin
respons
individu
respons
adapt
immun
respons
two
major
group
cell
mainli
antigenpres
cell
apc
lymphocyt
apc
like
macrophag
dendrit
cell
exhibit
antigenspecif
receptor
function
process
present
antigen
antigenspecif
receptor
tcell
lymphoyt
categoris
two
distinct
cell
type
name
blymphocyt
tlymphocyt
blymphocyt
essenti
compon
protect
us
invas
antigen
environ
blymphocyt
upon
interact
target
antigen
prolifer
produc
solubl
form
bcell
receptor
commonli
known
antibodi
human
immun
system
abil
produc
divers
collect
uniqu
antibodi
target
wide
rang
target
antibodi
circul
blood
lymphat
system
encount
foreign
antigen
manner
bcell
receptor
capabl
demonstr
high
target
specif
hypothesis
use
clonal
select
theori
molecular
level
bcell
undergo
sever
complex
stage
develop
becom
fulli
activ
antibodi
produc
cell
howev
complex
divers
natur
antibodi
develop
involv
genet
rearrang
somat
hypermut
crucial
immun
system
fight
possibl
foreign
antigen
encount
chapter
give
short
overview
blymphocyt
develop
includ
repertoir
gener
process
addit
also
highlight
concept
utilis
blymphocyt
repertoir
phage
display
librari
gener
focus
infecti
diseas
b
lymphocyt
name
discoveri
bursa
fabriciu
bone
marrow
differenti
pluripot
hematopoiet
stem
cell
preb
cell
gener
progenitor
cell
prob
cell
migrat
fetal
liver
earli
embryon
develop
fetal
liver
develop
matur
b
lymphocyt
mainli
settl
epithelia
lung
gutassoci
lymphoid
tissu
bcell
develop
earli
bone
marrowdepend
stage
concentr
along
function
rearrang
process
heavi
chain
hc
light
chain
lc
gene
segment
independ
rearrang
process
capabl
fabric
extend
bcell
repertoir
respons
express
divers
pool
antibodi
estim
divers
gener
gener
divers
antibodi
bcell
classifi
two
stage
compris
preand
postantigen
stimul
repertoir
exist
preantigen
stimul
categoris
preimmun
repertoir
estim
uniqu
antibodi
molecul
found
human
bodi
initi
repertoir
suffici
isol
antibodi
wide
rang
antigen
divers
preimmun
antibodi
repertoir
gener
allel
divers
variabl
gene
segment
v
j
recombin
junction
diversif
pair
heavi
light
chain
receptor
edit
variabl
gene
vgene
hc
result
rearrang
three
differ
gene
segment
variabl
v
divers
join
j
segment
howev
lc
gene
form
combin
two
gene
segment
v
j
gene
segment
gene
segment
exist
multipl
copi
select
differ
combin
gene
segment
construct
vgene
random
gene
rearrang
allow
format
initi
divers
antibodi
repertoir
human
heavi
chain
v
region
least
function
v
gene
segment
gene
segment
j
gene
segment
v
j
recombin
primari
somat
gene
rearrang
v
j
gene
segment
prior
antigen
exposur
mechan
happen
variabl
region
hc
lc
encod
antigen
recognit
site
sequenc
format
allow
hc
assembl
prior
lc
v
j
recombin
initi
introduct
dna
doublestrand
break
use
recombin
activ
gene
rag
protein
rag
rag
specif
recombin
signal
sequenc
rss
absenc
rag
protein
lead
failur
lymphocyt
develop
progenitor
stage
v
j
recombin
occur
recombin
process
guid
set
conserv
flank
dna
sequenc
locat
next
gene
segment
ensur
correct
recombin
flank
dna
sequenc
known
rss
conserv
heptam
nanom
sequenc
separ
spacer
either
bp
length
join
two
gene
segment
v
j
recombin
adapt
rule
v
j
gene
segment
flank
pair
bp
spacer
gene
segment
bp
spacer
flank
end
therefor
allow
join
gene
segment
v
j
gene
segment
ensur
v
gene
segment
combin
j
gene
segment
directli
bind
rag
protein
rss
allow
format
complex
initi
dna
doublestrand
break
dsb
gene
segment
rss
break
later
join
nonhomolog
endjoin
nhej
protein
addit
delet
nucleotid
addit
delet
gene
enhanc
divers
variabl
region
junction
diversif
howev
gene
produc
junction
diversif
function
eventu
lead
death
b
cell
gene
diversif
process
also
lead
format
b
cell
receptor
target
selfantigen
popul
b
cell
target
selfantigen
undergo
edit
process
term
receptor
edit
receptor
edit
function
elimin
selfreact
b
cell
system
b
cell
stimul
undergo
v
j
recombin
order
edit
receptor
enhanc
divers
antibodi
antibodi
gene
diversif
occur
postantigen
exposur
ultim
aim
divers
repertoir
upon
exposur
antigen
antibodi
perform
second
wave
diversif
enhanc
bind
affin
antigen
via
affin
matur
cumul
point
mutat
v
region
heavi
light
chain
induc
affin
matur
antibodi
somat
hypermut
shm
class
switch
recombin
csr
exampl
lead
affin
matur
antibodi
upon
stimul
antigen
shm
diversifi
v
region
alter
affin
antigen
bind
site
csr
chang
heavi
chain
constant
c
h
region
gener
differ
antibodi
isotyp
iga
igd
ige
igg
igm
shm
csr
initi
somat
mutat
v
region
constant
region
respect
also
report
activationinduc
cytidin
deaminas
aid
requir
shm
csr
trigger
mechan
aid
kda
protein
deamin
cytidin
residu
singlestrand
dna
ssdna
rna
doubl
strand
dna
dsdna
aid
caus
format
dna
lesion
later
repair
multipl
dna
repair
pathway
base
excis
repair
ber
mismatch
repair
mmr
nhej
protein
role
aid
diversif
process
evid
aid
defici
mice
human
unabl
carri
shm
csr
despit
happen
stage
b
cell
differenti
shm
csr
differ
biochem
process
mediat
differ
set
enzym
shm
occur
germin
center
gc
csr
occur
either
insid
outsid
gc
shm
region
specif
mechan
begin
base
pair
bp
downstream
transcript
start
site
tss
detect
far
kb
within
intron
region
j
c
exon
aid
deamin
cytosin
residu
v
region
product
deamin
lead
uracilguanin
ug
mismatch
mismatch
later
repair
dna
repair
mechan
base
excis
repair
mismatch
repair
incorpor
point
mutat
shm
v
j
exon
hc
lc
help
improv
antibodi
affin
shm
occur
frequenc
mutat
per
base
pair
per
gener
million
time
greater
mutat
rate
gene
gener
singl
base
substitut
prefer
insert
delet
indel
shm
also
shm
report
favour
certain
motif
wrci
w
r
g
c
c
revers
complement
rgyw
motif
therefor
shm
activ
cdr
region
motif
larg
present
two
third
shm
induc
substitut
mutat
transit
mutat
prefer
shm
antibodi
undergon
shm
produc
higher
affin
antigen
receptor
compet
lower
affin
inact
antibodi
select
process
enabl
higher
affin
antibodi
target
specif
antibodi
concentr
csr
mechan
allow
antibodi
isotyp
switch
initi
differ
mechan
differ
site
bodi
csr
switch
antibodi
isotyp
via
dna
delet
recombin
igh
constant
region
upon
exposur
antigen
therefor
csr
vital
antibodi
matur
infect
vaccin
defect
csr
associ
rang
diseas
csr
occur
switch
sequenc
locat
upstream
constant
region
gene
c
h
exon
except
exon
differ
immunoglobulin
isotyp
encod
differ
c
h
exon
arrang
order
heavi
chain
therebi
replac
c
h
exon
could
give
rise
igg
iga
ige
respect
howev
v
region
antibodi
remain
intact
unchang
igd
immunoglobulin
isotyp
five
gener
via
altern
splice
primari
transcript
encod
igm
via
csr
divers
gener
via
molecular
mechan
predominantli
respons
assort
repertoir
antibodi
gene
variat
provid
flexibl
antibodi
repertoir
gener
antibodi
wide
array
antigen
vari
specif
affin
antibodi
repertoir
reflect
threat
encount
immun
system
differ
repertoir
form
result
therefor
variat
antibodi
repertoir
individu
similar
infect
differ
infect
expect
direct
influenc
repertoir
antibodi
isol
differ
antibodi
librari
use
phage
display
histor
applic
antibodi
biomed
applic
first
shown
applic
antisera
hyperimmun
anim
treat
botul
diphtheria
use
antisera
highlight
potenti
antibodi
although
polyclon
level
magic
bullet
target
infect
treatment
introduct
hybridoma
technolog
product
monoclon
antibodi
mab
realis
hybridoma
technolog
requir
fusion
immort
myeloma
cell
antibodi
produc
spleen
cell
gener
hybridoma
exhibit
characterist
myeloma
spleen
cell
characterist
allow
infinit
gener
mab
vitro
howev
approach
requir
use
murin
deriv
spleen
cell
postimmun
report
trigger
human
antimous
antibodi
hama
respons
upon
administr
greatli
limit
therapeut
applic
murin
mab
human
may
result
reduc
efficaci
time
case
anaphylaxi
complic
associ
use
anim
deriv
mab
result
string
technolog
advanc
like
cdr
graft
antibodi
human
reduc
murinenatur
antibodi
gener
ultim
abil
gener
fulli
human
antibodi
perceiv
solut
issu
introduct
phage
display
technolog
revolution
way
antibodi
produc
vitro
twentieth
centuri
applic
vitro
display
technolog
like
phage
display
allow
gener
fulli
human
mab
greater
amount
control
manner
howev
phage
display
longer
display
method
avail
product
human
mab
exampl
vitro
display
technolog
use
mab
gener
ribosom
display
yeast
surfac
display
bacteri
surfac
display
mrna
display
introduct
xenograph
mice
technolog
human
antibodi
gener
also
assist
gener
monoclon
antibodi
prospect
affin
matur
phage
display
promis
vitro
display
method
utilis
success
isol
target
specif
antibodi
exploit
ff
phage
filament
phage
import
advantag
phage
display
make
prefer
altern
robust
simplic
stabil
phage
particl
allow
select
desir
antibodi
differ
target
predefin
condit
phage
display
technolog
first
introduc
georg
smith
display
peptid
surfac
phage
particl
fusion
coat
protein
ultim
exchang
antibodi
fragment
isol
mab
due
nonlyt
characterist
filament
phage
fd
commonli
use
phage
display
infect
gram
neg
bacteria
carri
f
pilu
fundament
concept
phage
display
lie
direct
physic
linkag
genotyp
phenotyp
protein
peptid
encod
genotyp
usual
display
phage
surfac
fusion
phage
coat
protein
pviii
piii
even
though
fusion
coat
protein
pvii
pix
also
report
ntermin
found
vital
phage
infect
henc
protein
interest
fuse
affect
effici
phage
infect
propag
phage
display
take
advantag
natur
process
phage
infect
propag
replic
process
aid
helper
phage
system
use
phagemid
vector
helper
phage
use
combin
phagemid
system
provid
necessari
coat
protein
well
wildtyp
phage
packag
shown
fig
phagemid
vector
uniqu
design
contain
featur
bacteri
express
plasmid
well
phage
replic
plasmid
phagemid
normal
design
harbour
antibodi
gene
fusion
giii
therefor
helper
phage
function
sourc
remain
wildtyp
protein
requir
phage
replic
morphogenesi
assembl
process
mab
gener
antibodi
phage
display
requir
presenc
antibodi
librari
harbour
approxim
phage
particl
present
uniqu
antibodi
clone
physic
isol
enrich
target
specif
mab
divers
librari
perform
via
biopan
biopan
term
coin
describ
siev
process
posit
clone
divers
librari
subsequ
augment
posit
popul
biopan
process
involv
sever
repetit
cycl
bind
wash
amplif
posit
phage
clone
predomin
popul
present
process
involv
immobil
target
antigen
variou
solid
surfac
polystyren
plate
microbead
nitrocellulos
blot
column
matrix
immunoassay
tip
antibodi
phage
librari
introduc
bound
target
antigen
left
incub
allow
affin
base
captur
antibodi
bear
phage
particl
antigen
unbound
antibodyphag
particl
remov
wash
remain
bound
phage
particl
elut
use
acidbas
elut
enzym
base
digest
elut
phage
particl
amplifi
reinfect
e
coli
fresh
cycl
phage
packag
new
popul
phage
particl
readi
use
ensu
round
biopan
cycl
repeat
round
ensur
continu
enrich
target
popul
phage
particl
vari
wash
elut
condit
custom
characterist
isol
mab
simul
differ
environ
stringenc
isol
mab
featur
particular
characterist
major
limit
associ
e
coli
fold
machineri
abil
provid
better
display
effici
smaller
version
antibodi
fragment
instead
full
antibodi
format
phage
surfac
howev
present
full
length
igg
use
bacteri
periplasm
display
previous
demonstr
yield
antibodi
nanomolar
rang
bind
affin
even
use
smaller
antibodi
fragment
distinct
advantag
term
tissu
penetr
smaller
antibodi
fragment
abl
penetr
tissu
higher
efficaci
without
compromis
affin
specif
diminut
size
antibodi
fragment
work
favour
bacteri
express
host
allow
easier
faster
express
recombin
antibodi
sever
common
antibodi
format
display
phage
includ
singlechain
fragment
variabl
scfv
fragment
antigen
bind
fab
domain
antibodi
scfv
format
prefer
antibodi
format
use
phage
display
prone
degrad
easier
express
function
form
bacteria
scfv
format
made
variabl
heavi
chain
v
h
variabl
light
chain
v
l
domain
interconnect
glycineserin
gs
linker
applic
linker
also
provid
new
fab
molecul
form
singl
chain
fab
scfab
fragment
phage
display
howev
choic
fragment
use
librari
gener
depend
downstream
appli
schemat
represent
phage
particl
bear
antibodi
fragment
display
gene
encod
scfv
fragment
fuse
giii
phagemid
introduct
bacteria
carri
f
pilu
infect
scfv
fuse
giii
phagemid
helper
phage
allow
helper
phage
provid
necessari
protein
requir
phage
packag
cation
antibodi
possibl
engin
new
format
allow
graft
variabl
domain
format
engin
subsequ
format
freedom
format
exchang
allow
improv
applic
antibodi
biomed
applic
even
choic
format
use
also
take
account
abil
clone
larg
divers
collect
clone
form
librari
phage
display
select
addit
format
convers
scfv
full
igg
report
caus
loss
target
affin
larg
due
conform
chang
structur
postconvers
therefor
proper
consider
design
requir
format
exchang
antibodi
fragment
carri
highlight
earlier
basic
requir
antibodi
phage
display
access
antibodi
librari
screen
antibodi
librari
use
asset
antibodi
develop
program
appli
variou
target
multipl
applic
gener
antibodi
librari
classifi
four
categori
name
immun
semisynthet
synthet
librari
classif
antibodi
librari
mainli
influenc
sourc
antibodi
v
gene
librari
gener
antibodi
librari
construct
use
v
gene
nonimmun
donor
immun
antibodi
librari
howev
construct
util
antibodi
v
gene
immun
donor
infect
individu
synthet
semisynthet
librari
construct
use
synthes
dna
oligonucleotid
repertoir
divers
devoid
natur
immun
matur
process
chapter
focu
principl
characterist
librari
includ
applic
antibodi
deriv
librari
combat
infecti
diseas
antibodi
librari
construct
use
b
cell
unimmun
healthi
donor
normal
focus
igm
isotyp
librari
supposedli
abl
use
isol
mab
antigen
process
involv
gener
antibodi
librari
well
establish
describ
numer
public
human
natur
antibodi
repertoir
approxim
size
thousand
time
larger
murin
antibodi
repertoir
howev
antibodi
isol
antibodi
librari
usual
exhibit
lower
affin
compar
antibodi
isol
immun
librari
repertoir
would
undergon
vivo
affin
matur
produc
higher
affin
antibodi
antibodi
librari
gener
sever
critic
aspect
monitor
includ
librari
size
repertoir
divers
determin
qualiti
librari
case
librari
larger
librari
size
prefer
ensur
higher
affin
mab
isol
correl
larger
librari
size
higher
affin
mab
report
sever
instanc
high
affin
clone
success
retriev
larger
size
librari
compar
smaller
size
antibodi
librari
actual
sourc
antibodi
gene
retriev
vital
consider
construct
process
antibodi
librari
antibodi
gene
could
sourc
peripher
blood
mononuclear
cell
pbmc
bone
marrow
tonsil
spleen
howev
b
cell
variou
stage
differ
degre
mutat
b
cell
obtain
bone
marrow
b
cell
tonsil
mutat
degre
mutat
advers
effect
repertoir
librari
therefor
highli
mutat
v
gene
tonsil
ideal
choic
antibodi
librari
construct
suitabl
immun
librari
b
cell
better
repres
raw
v
j
recombin
bone
marrow
yet
encount
antigen
divers
antibodi
librari
larg
depend
number
uniqu
antibodi
sequenc
success
clone
librari
b
cell
usual
taken
peripher
blood
construct
human
antibodi
librari
method
extract
less
invas
compar
bone
marrow
extract
peripher
blood
contain
high
proport
b
cell
make
peripher
blood
good
sourc
b
cell
first
antibodi
librari
report
construct
use
peripher
blood
lymphocyt
pbl
unimmun
donor
estim
librari
size
greater
librari
success
use
isol
solubl
antibodi
fragment
hapten
good
affin
gener
concern
associ
antibodi
librari
true
natur
sampl
naiveti
due
subject
natur
term
healthi
unlik
donor
never
infect
throughout
lifetim
make
realist
imposs
obtain
truli
sampl
healthi
individu
would
recov
prior
infect
immun
stage
life
vaccin
report
increas
antigenspecif
repertoir
could
result
skew
repertoir
gener
addit
memori
cell
immun
system
capabl
recogn
past
infect
could
contribut
chang
antibodi
repertoir
common
consider
librari
sampl
collect
includ
healthi
donor
without
immunosuppress
treatment
well
antigen
exposur
histori
age
genotyp
chromatin
structur
gener
protocol
construct
antibodi
librari
use
pbmc
demonstr
fig
naiv
antibodi
librari
construct
start
blood
sampl
collect
healthi
popul
b
cell
whole
blood
isol
use
ficollhypaqu
densiti
gradient
centrifug
util
densiti
differ
mononuclear
cell
fig
gener
step
involv
antibodi
librari
gener
gener
antibodi
librari
start
blood
sampl
collect
healthi
donor
total
rna
prepar
use
templat
revers
transcript
first
strand
cdna
use
gene
specif
primer
cdna
amplifi
polymeras
chain
reaction
pcr
gener
dna
amplicon
second
round
pcr
perform
dna
sampl
introduc
cut
site
restrict
enzym
amplicon
clone
phagemid
transform
suitabl
bacteria
cell
element
blood
separ
mononuclear
cell
lymphocyt
monocyt
platelet
stay
top
ficol
layer
dens
enough
penetr
ficol
layer
granulocyt
hand
sediment
bottom
ficol
layer
due
increas
densiti
upon
contact
ficol
medium
red
blood
cell
also
sediment
bottom
ficol
solut
due
aggreg
ficol
mononuclear
cell
layer
wash
centrifug
remov
platelet
remain
supernat
upon
obtain
b
cell
mrna
isol
immedi
revers
transcrib
cdna
revers
transcript
mrna
carri
use
either
random
hexam
primer
antibodi
specif
primer
antibodi
specif
primer
igm
constant
region
specif
primer
allow
cdna
synthesi
antibodi
sequenc
igm
isotyp
howev
prime
use
random
hexam
allow
five
antibodi
class
iga
igd
ige
igg
igm
amplifi
highli
divers
repertoir
therefor
random
hexam
use
often
synthes
first
strand
cdna
b
cell
mrna
gener
antibodi
librari
case
prefer
isotyp
antibodi
librari
gener
igm
howev
circul
memori
cell
express
igm
may
due
somat
hypermut
upon
exposur
antigen
upon
obtain
b
cell
cdna
variabl
v
region
heavi
chain
v
h
light
chain
v
l
amplifi
use
defin
set
primer
encompass
human
antibodi
gene
repertoir
differ
primer
set
publish
year
amplif
v
gene
howev
v
gene
primer
design
evolv
year
due
addit
inform
avail
improv
sequenc
technolog
bioinformat
analysi
improv
databas
antibodi
v
gene
sequenc
next
gener
sequenc
shed
much
light
antibodi
gene
usag
v
gene
famili
coverag
addit
new
antibodi
gene
sequenc
allow
new
primer
set
design
improv
gene
coverag
improv
gene
coverag
primer
set
great
influenc
repertoir
final
antibodi
librari
gener
help
ensur
possibl
antibodi
gene
repres
librari
well
increas
possibl
combin
hc
lc
gene
first
v
gene
amplif
usual
done
gene
specif
primer
without
introduct
flank
region
amplif
bia
pcr
common
concern
could
influenc
final
repertoir
librari
antibodi
gene
usag
evenli
distribut
variat
result
previou
infect
addit
variat
individu
immun
respons
therefor
highli
repres
primer
set
import
ensur
uniqu
gene
famili
poorli
present
templat
also
amplifi
second
round
pcr
amplif
perform
introduc
desir
restrict
site
clone
phagemid
vector
sever
differ
strategi
construct
antibodi
librari
common
approach
use
construct
antibodi
librari
either
twostepthreestep
clone
pcr
assembl
shown
fig
twostep
clone
light
chain
gene
first
amplifi
introduc
glycineserin
linker
clone
phagemid
vector
establish
intermedi
librari
clone
amplifi
heavi
chain
gene
intermedi
librari
done
form
full
scfv
format
librari
orient
v
gene
clone
first
influenc
higher
divers
hc
region
case
threestep
clone
use
construct
antibodi
librari
approach
independ
v
h
v
l
librari
first
clone
function
intermedi
librari
librari
digest
ligat
togeth
form
full
antibodi
librari
contain
v
h
v
l
repertoir
pcr
assembl
v
h
v
l
gene
amplifi
introduc
gs
linker
clone
pcr
assembl
use
assembl
three
fragment
form
full
scfv
format
assembl
fragment
digest
restrict
enzym
clone
upstream
gene
iii
coat
protein
phagemid
ligat
product
antibodi
sequenc
phagemid
transform
bacteri
cell
carri
f
pilu
mrf
e
coli
ss
choic
cell
use
must
high
transform
effici
even
high
number
transform
requir
overcom
limit
e
coli
transform
order
gener
larg
antibodi
librari
librari
divers
normal
calcul
base
number
coloni
form
serial
dilut
transform
plate
agar
incub
overnight
librari
develop
often
target
highest
librari
size
possibl
howev
uphil
task
due
limit
mention
earlier
even
averag
size
antibodi
librari
rang
higher
direct
correl
librari
size
antibodi
affin
spur
need
gener
larg
librari
size
order
isol
high
affin
antibodi
without
need
improv
affin
grow
concern
term
global
health
emerg
new
infecti
diseas
reemerg
old
diseas
situat
intensifi
concern
diseas
might
eventu
becom
pandem
advent
antibodi
base
technolog
direct
impact
global
health
antibodi
use
biomolecul
diagnost
therapeut
applic
applic
antibodi
diagnost
allow
major
role
diseas
manag
earli
detect
system
critic
fight
infect
diseas
prevent
last
decad
identif
antibiot
resist
highlight
vulner
human
popul
toward
new
infect
highlight
need
new
altern
treatment
includ
antibodi
base
therapi
antibodi
base
therapi
appear
promis
solut
infecti
diseas
due
high
specif
flexibl
provid
term
modif
allow
direct
program
specif
mechan
treatment
specif
diseas
gener
immun
librari
prefer
gener
antibodi
infecti
diseas
relat
target
due
skew
antibodi
repertoir
result
exposur
infect
addit
high
affin
antibodi
could
isol
immun
librari
due
vivo
affin
matur
antigen
present
therefor
preferenti
repertoir
particular
diseas
mean
librari
smaller
size
repertoir
suffici
one
major
drawback
immun
librari
inabl
appli
across
wide
rang
antigen
mean
new
librari
construct
time
antibodi
antigen
differ
infect
gener
major
advantag
librari
huge
divers
show
bia
toward
antigen
make
univers
sourc
antibodi
target
antigen
use
antibodi
base
therapi
start
earli
sera
immunis
anim
appli
cure
bacteri
infect
clostridium
tetani
corynebacterium
diphtheria
sinc
also
appli
diseas
tetanu
hepat
b
measl
rabi
varicella
vaccinia
year
develop
antibodi
technolog
allow
antibodi
produc
faster
rate
vitro
contribut
increas
antibodi
discoveri
project
mani
differ
diseas
antibodi
gener
use
tradit
method
requir
live
host
difficult
deal
target
toxic
host
overcom
use
antibodi
librari
coupl
antibodi
phage
display
technolog
allow
isol
antibodi
antigen
toxic
detriment
host
instanc
hemolysin
e
hlye
toxin
produc
salmonella
enterica
serovar
typhi
pore
form
toxin
antigen
human
may
pose
challeng
convent
antibodi
gener
techniqu
howev
solubl
scfv
mab
hlye
toxin
success
isol
human
scfv
librari
construct
healthi
donor
donor
consist
equal
distribut
donor
three
ethnic
group
malay
chines
indian
equal
gender
distribut
enhanc
divers
librari
combinatori
mix
v
h
v
l
chain
perform
heavi
light
chain
randomli
mix
librari
gener
twostep
clone
insert
light
chain
follow
heavi
chain
abil
har
contrast
immun
respons
differ
individu
result
vari
gene
rearrang
gene
pair
usag
allow
improv
divers
librari
improv
divers
ensur
higher
repertoir
antibodi
gener
improv
affin
larg
librari
size
also
signific
role
determin
antibodi
qualiti
isol
librari
anoth
primari
exampl
applic
librari
abil
gener
antibodi
spore
bacillu
anthraci
result
death
post
inhal
spore
b
anthraci
potent
biolog
threat
abus
bioweapon
anthrax
spore
intent
mail
washington
dc
toxic
natur
spore
make
immun
antibodi
gener
imposs
would
like
kill
host
therefor
isol
human
antibodi
capabl
bind
live
nativ
spore
possibl
use
scfv
librari
biopan
scfv
librari
isol
two
clone
differ
specif
affin
spore
bacillu
strain
well
recogn
differ
epitop
analysi
clone
reveal
bia
v
h
v
l
pair
repertoir
exposur
spore
human
immun
system
fab
librari
later
construct
combin
v
h
v
l
gene
isol
posit
scfv
clone
aim
reduc
cross
reactiv
bascillu
strain
chain
shuffl
techniqu
introduc
fab
librari
increas
divers
v
h
v
l
gene
clone
isol
fab
librari
show
much
lower
cross
reactiv
spore
strain
process
envis
pan
human
scfv
librari
spore
bacillu
subtili
ifo
anoth
publish
work
bacillu
anthraci
focu
protect
antigen
essenti
anthrax
toxic
mechan
sever
scfv
bind
isol
librari
highest
binder
exhibit
k
nm
librari
gener
via
threestep
clone
v
h
v
l
gene
first
clone
separ
plasmid
vector
gener
separ
v
h
v
l
librari
advantag
individu
librari
suppli
endless
materi
scfv
assembl
size
scfv
librari
construct
human
antibodi
librari
also
use
isol
antibodi
fragment
tuberculosi
tb
antigen
tb
appear
one
lead
fatal
microbi
infecti
diseas
worldwid
caus
mycobacterium
tuberculosi
librari
construct
use
b
cell
donor
caucasian
african
indian
chines
origin
use
twostep
clone
appli
clone
heavi
light
chain
antibodi
creat
two
librari
heavi
chain
repertoir
differ
light
chain
lambda
kappa
repertoir
librari
valid
antigen
ensur
qualiti
librari
librari
use
pan
antigen
b
complex
mtb
five
scfv
clone
success
isol
confirm
dna
sequenc
four
clone
lambda
light
chain
one
kappa
light
chain
abil
phage
display
methodolog
appli
array
differ
target
type
allow
isol
antibodi
variou
target
antibodi
librari
also
use
pan
intact
bacteria
antibodi
gener
scfv
librari
isol
speciesspecif
antibodi
lactobacillu
acidophilu
atcc
prior
fac
quantif
genom
sequenc
gener
scfv
librari
incorpor
use
crelox
system
abl
gener
highli
divers
librari
size
phagemid
lox
site
use
infect
cre
recombinas
express
bacteria
high
number
phagemid
abl
enter
singl
bacterium
shuffl
v
h
v
l
occur
lox
site
introduc
v
h
v
l
gene
act
scfv
linker
select
lox
site
restrict
singl
basic
amino
acid
reduc
proteolysi
remov
stop
codon
least
hydrophob
natur
analysi
show
isol
scfv
recognis
surfac
layer
slpa
protein
l
acidophilu
abund
antibodi
demonstr
high
degre
specif
hemagglutinin
ha
region
influenza
virus
respons
antigen
influenza
virus
extens
mutat
region
enabl
emerg
multipl
antigen
distinct
strain
overcom
issu
target
conserv
region
protein
outsid
antigen
site
becom
one
option
avoid
viru
escap
combin
pan
strategi
perform
isol
fabphag
antibodi
away
ha
antigen
site
toward
conserv
region
ha
thirti
three
fab
antibodi
fragment
multipl
ha
success
isol
human
fab
phage
display
librari
humanyx
pte
ltd
singapor
five
antibodi
exhibit
specif
toward
conserv
region
vital
fusion
viral
cell
membran
asid
isol
antibodi
intact
bacteria
antibodi
phage
librari
also
appli
success
isol
antibodi
intact
viru
particl
human
scfv
librari
appli
pan
intact
viru
particl
venezuelan
equin
enceph
viru
veev
interest
public
shown
isol
antibodi
viru
protein
intact
viru
particl
size
scfv
librari
appli
subject
three
round
pan
preselect
step
perform
incub
phage
librari
concentr
supernat
noninfect
vero
cell
minim
fals
posit
result
solubl
scfv
use
elisa
instead
scfv
phage
isol
scfv
analys
integr
databas
germlin
variabl
gene
immunoglobulin
loci
human
result
demonstr
variabl
domain
light
chain
consist
heavi
chain
dengu
viru
flavivirida
famili
singl
strand
posit
strand
rna
genom
post
translat
modif
polypeptid
give
rise
three
structur
protein
capsid
membran
envelop
seven
nonstructur
protein
nonstructur
protein
nonstructur
protein
essenti
viral
replic
subdivid
distinct
function
domain
target
domain
provid
import
inform
dengu
replic
develop
inhibitor
dengu
viru
human
fab
librari
humanyx
pte
ltd
singapor
use
screen
binder
protein
biotinyl
bind
streptavidin
magnet
bead
prior
pan
concentr
immobilis
protein
reduc
round
increas
wash
step
pan
ten
uniqu
clone
obtain
observ
bind
proteas
domain
helicas
domain
domain
differ
dengu
serotyp
one
clone
demonstr
abil
bind
protein
dengu
serotyp
high
bind
affin
nm
elisa
well
surfac
plasmon
reson
spr
k
nm
similar
pan
strategi
appli
isol
antibodi
protein
howev
six
uniqu
clone
isol
specif
dengu
viru
serotyp
henc
pan
perform
altern
dengu
serotyp
enrich
clone
abl
recognis
protein
serotyp
two
crossreact
fab
one
specif
fab
obtain
clone
incub
array
overlap
peptid
span
domain
region
map
epitop
bind
site
abil
isol
crossreact
clone
sever
serotyp
well
serotyp
specif
antigen
show
flexibl
afford
use
antibodi
librari
variou
endeavour
taken
select
good
binder
antibodi
phage
librari
variou
antigen
approach
increas
librari
size
enhanc
clone
strategi
improv
pan
protocol
demonstr
retriev
good
binder
anoth
approach
report
use
proteas
sensit
helper
phage
method
allow
high
throughput
screen
naiv
librari
wide
rang
antigen
proteasecleavag
sequenc
insert
domain
domain
piii
elimin
background
contribut
helper
phage
helper
phage
one
two
round
select
would
need
sinc
number
select
increas
chanc
obtain
new
binder
scfv
rabi
viru
success
isol
human
scfv
librari
size
individu
clone
rabi
viru
consid
difficult
target
due
presenc
limit
amount
target
mixtur
might
contribut
enrich
background
nonspecif
binder
hendra
viru
hev
belong
henipaviru
genu
paramyxovirina
depend
two
major
membraneanchor
envelop
glycoprotein
g
f
infect
viru
caus
mortal
anim
human
host
infect
cell
envelop
glycoprotein
fuse
cell
membran
fab
antibodi
librari
approxim
size
use
pan
solubl
form
glycoprotein
hendra
g
sg
librari
construct
collect
peripher
blood
b
cell
healthi
donor
seven
uniqu
fab
isol
librari
demonstr
longer
v
h
among
stronger
binder
compar
weakli
bound
fab
isol
fab
produc
measur
inhibitori
activ
report
gene
assay
inhibit
syncytium
format
later
convers
particular
potent
fab
full
antibodi
format
exhibit
neutral
potenc
candida
albican
common
pathogen
human
usual
attack
immunocompromis
individu
weak
immun
system
report
protein
carbohydr
moieti
c
albican
cell
wall
elicit
strong
immunolog
respons
human
henc
isol
antibodi
abl
bind
moieti
could
lead
better
understand
antibodi
reactiv
toward
surfac
antigen
therapeut
purpos
combinatori
phage
display
scfv
librari
use
pan
surfac
antigen
c
albican
combinatori
librari
consist
two
scfv
librari
one
deriv
lambda
famili
anoth
one
deriv
kappa
famili
pan
antigen
use
roughli
phage
librari
pan
v
l
v
l
librari
manag
obtain
enrich
respect
three
scfv
clone
isol
confirm
bind
blastoconidia
surfac
antigen
via
immunofluoresc
assay
ifa
enzymelink
immunosorb
assay
elisa
western
blot
malaria
lifethreaten
diseas
caus
plasmodium
parasit
transmit
mosquito
five
speci
plasmodium
falciparum
common
lethal
type
lead
morbid
mortal
p
falciparum
histidinerich
protein
common
candid
detect
p
falciparum
infect
remain
bloodstream
day
upon
infect
scfv
librari
appli
isol
antibodi
protect
antigen
bacillu
anthraci
mention
earlier
also
use
pan
highlight
flexibl
afford
librari
use
variou
diseas
target
simultan
monoclon
antibodi
recognis
import
class
drug
especi
autoimmun
diseas
cancer
infecti
diseas
accommod
increas
interest
biomed
applic
antibodi
antibodi
phage
display
technolog
provid
altern
rapid
discoveri
broad
utilis
novel
highli
specif
fulli
human
antibodi
sinc
introduct
monoclon
antibodi
technolog
kohler
milstein
antibodi
becom
import
biomolecul
due
capabl
appli
variou
field
importantli
diagnost
therapeut
vaccin
develop
potenti
applic
antibodi
isol
librari
diagnost
demonstr
public
isol
scfv
fab
antibodi
fragment
nativ
spore
bacillu
subtili
ifo
label
two
differ
fluoresc
dye
fitc
rhodaminenhydroxysuccinimid
direct
indirect
detect
fluoresc
microscop
detect
signal
greatli
amplifi
fluoresc
dye
label
highcopi
number
phage
coat
protein
pviii
antibodi
phage
particl
direct
detect
individu
spore
made
possibl
fluorescentlabel
antibodyphag
clone
spore
bind
antibodi
could
incorpor
detect
system
highflowr
fluidiz
bed
solid
phase
captur
electrochemiluminesc
immunoassay
eclia
magnet
particl
fluorogen
immunoassay
mpfia
anoth
exampl
demonstr
l
acidophilu
speci
specif
scfv
isol
phage
display
technolog
result
scfv
isol
appli
fac
enrich
l
acidophilu
result
genom
coverag
envis
speci
specif
antibodi
could
appli
enrich
low
abund
organ
commun
could
lead
better
taxonom
identif
genom
recoveri
prior
genom
sequenc
convers
antibodi
fragment
full
igg
format
fc
format
alway
prefer
therapeut
fab
antibodi
fragment
isol
ha
region
viru
convert
full
human
igg
format
antibodi
show
bind
conserv
region
exhibit
promis
neutral
efficaci
anoth
public
report
potenti
therapeut
applic
hendra
viru
nipah
viru
via
convers
potent
fab
fulllength
format
shown
much
better
cell
fusion
inhibitori
activ
lesser
inhibitori
concentr
requir
scfv
clone
antigen
tb
convert
scfvfc
yumab
format
abl
serv
potenti
biomark
diagnost
tb
valid
bind
scfvfc
antibodi
antigen
perform
titrat
elisa
sandwich
elisa
lowest
detect
limit
achiev
ngml
ngml
respect
later
antibodi
put
onto
platform
later
flow
immunoassay
lfia
detect
b
conjug
antibodi
nm
colloid
gold
assay
abl
detect
antigen
ngml
mtb
cultur
filtrat
also
success
detect
use
immunoblot
analys
reduc
gel
analysi
via
tape
station
despit
low
instanc
antibodi
librari
appli
infecti
diseas
antibodi
deriv
librari
could
appli
similar
fashion
infecti
diseas
therapi
like
oncolog
autoimmun
antibodi
play
crucial
role
neutral
infect
viru
block
bind
site
receptor
viru
host
cell
class
antibodi
known
neutral
antibodi
nab
neutral
defin
reduct
viral
infect
via
bind
antibodi
viral
surfac
particl
lead
block
viral
replic
process
viral
infect
requir
attach
viru
host
cell
membran
differ
virus
may
util
differ
approach
infect
nake
virus
adenovirus
papillomavirus
abl
penetr
host
cell
membran
enter
cytoplasm
inject
genom
membran
envelop
virus
dengu
virus
zika
virus
ebola
virus
fuse
envelop
host
membran
attach
therefor
antibodi
bind
influenza
viru
membran
protein
abl
imped
fusion
influenza
virus
host
cell
membran
target
viral
envelop
protein
envelop
virus
becom
attract
option
diagnost
therapi
sinc
envelop
protein
express
viral
surfac
therefor
access
antibodi
attach
exampl
dengu
envelop
e
protein
common
target
neutral
antibodi
also
vaccin
develop
sinc
contain
neutralis
epitop
bind
motif
viru
entri
host
cell
human
fab
mab
shown
bind
four
dengu
serotyp
enzymelink
immunosorb
assay
elisa
could
neutral
dengu
serotyp
mab
abl
neutralis
dengu
viru
nanogram
level
cryoelectron
microscopi
cryoem
show
one
fab
abl
bind
across
three
e
protein
engag
domain
crucial
infect
moreov
antibodi
could
prevent
viru
enter
host
cell
attach
preattach
neutral
test
show
effici
ng
antibodi
case
polyclon
antibodi
work
better
detect
viral
protein
dengu
protein
protein
work
cofactor
proteas
activ
protein
small
size
make
difficult
target
whole
viru
particl
use
polyclon
antibodi
protein
gener
via
gene
protein
immunis
mice
western
blot
immunofluoresc
assay
confirm
polyclon
antibodi
gener
abl
recognis
nativ
denatur
form
protein
certain
case
ebola
viru
ebov
infect
antibodi
cocktail
use
nab
administr
antibodi
cocktail
instead
singl
antibodi
shown
promis
result
nonhuman
primat
sever
antibodi
cocktail
ebov
develop
recent
year
includ
zmab
zmapp
combin
demonstr
success
therapeut
activ
zmapp
improv
version
two
antibodi
cocktail
zmab
report
surviv
rate
administ
rhesu
macaqu
despit
treatment
initi
day
infect
antibodi
cocktail
found
target
sever
vulner
site
glycoprotein
gp
neutral
antibodi
target
base
gp
nonneutr
antibodi
bind
glycan
cap
mucinlik
domain
function
extern
domain
viral
attach
fusion
allow
cumul
effect
neutral
viru
replic
prevent
viru
surviv
latest
antibodi
cocktail
success
protect
nonhuman
primat
ebola
viru
diseas
includ
viremia
combin
antibodi
function
target
differ
region
ebola
viru
improv
efficaci
antibodi
found
recogn
base
ebola
viru
gp
trimer
prevent
access
cathepsincleavag
loop
prevent
proteolyt
cleavag
gp
requir
viru
entri
howev
abl
interact
glycan
cap
inner
chalic
gp
antibodi
remain
associ
glycan
cap
even
proteolyt
remov
aid
inhibit
bind
cleav
gp
receptor
combin
effect
two
antibodi
provid
basi
viru
neutral
protect
ebola
viru
cocktail
approach
use
sever
differ
antibodi
vari
specif
function
offer
broader
coverag
prevent
escap
viru
asid
ebov
infect
antibodi
cocktail
also
appli
viral
infecti
diseas
rabi
viru
sar
coronaviru
hiv
hepat
b
viru
virus
applic
antibodycocktail
longer
someth
new
formul
commerci
differ
antibodi
cocktail
separ
b
cell
cell
sampl
merck
bdbioscienc
miltenyi
biotec
howev
applic
antibodi
cocktail
therapi
especi
infecti
diseas
yet
realis
clinic
set
one
major
attract
use
antibodi
therapi
abil
antibodi
induc
cytotox
antibodi
abl
lyse
target
molecul
trigger
antibodi
depend
cell
mediat
cytotox
adcc
complement
depend
cytotox
cdc
activ
adcc
use
immuneeffector
cell
macrophag
natur
killer
cell
cdc
function
activ
cascad
complement
protein
exampl
rituximab
rituxan
target
panbcel
marker
induc
cell
death
regard
sever
pathogen
varicella
tetanu
respiratori
syncyti
viru
rsv
rabi
hepat
b
report
show
success
prophylact
use
antibodi
expos
individu
case
immunodefici
immunosuppress
individu
especi
hiv
infect
patient
antibodi
therapi
viabl
option
therapi
provid
immun
infecti
pathogen
without
give
rise
tcell
stimul
promot
hiv
growth
addit
antibodi
given
infect
vaccin
avail
exampl
ebola
marburg
virus
antibodydrug
conjug
adc
complex
antibodi
coval
join
potent
cytotox
drug
use
variou
conjug
techniqu
conjug
wide
appli
cancer
therapi
due
capabl
differenti
healthi
diseas
state
tissu
novel
antibodyantibiot
conjug
develop
elimin
intracellular
aureu
one
major
caus
bacteri
infect
world
anti
aureu
antibodi
screen
care
select
peripher
blood
patient
recov
variou
aureu
infect
link
highli
efficaci
antibiot
via
capthesincleav
linker
conjug
elimin
aureu
via
two
mechan
engulf
host
cell
let
intracellular
proteas
cleav
releas
antibiot
activ
form
bind
conjug
bacterium
deliv
antibiot
within
phagosom
kill
bacteri
conjug
abl
kill
aureu
insid
human
macrophag
endotheli
epitheli
cell
line
antibodydrug
conjug
would
new
avenu
therapi
infecti
diseas
also
diseas
like
cancer
autoimmun
diseas
conjug
drug
potent
molecul
antibodi
might
promis
way
overcom
limit
possess
intact
antibodi
convent
antibiot
treatment
librari
like
prove
promis
diagnost
therapeut
tool
infecti
diseas
come
futur
due
great
divers
immunesystemindepend
natur
give
endless
possibl
isol
antibodi
target
wide
array
diseas
antigen
antibodi
base
therapi
inde
comeback
trail
disappoint
murin
mab
provok
undesir
immun
respons
human
upon
administr
despit
lot
mab
approv
clinic
usag
one
mab
palivizumab
approv
treatment
infecti
diseas
antibodi
base
therapi
infecti
diseas
still
underdevelop
neglect
due
lack
research
interest
compar
cancer
pandem
diseas
immunis
antibodi
librari
alway
prefer
develop
antibodi
infecti
diseas
antigen
skew
repertoir
immunis
librari
allow
isol
highaffin
bind
antibodi
howev
rate
emerg
reemerg
infecti
diseas
gener
diseas
specif
immunis
librari
feasibl
option
henc
good
qualiti
antibodi
librari
satisfactori
size
divers
becom
impecc
tool
gener
antibodi
infecti
diseas
despit
antibodi
isol
antibodi
librari
might
satisfactori
bind
affin
advanc
molecular
technolog
could
utilis
overcom
limit
believ
aid
newer
technolog
better
qualiti
human
librari
could
construct
isol
better
qualiti
antibodi
combat
infecti
diseas
antibodi
phage
librari
forese
role
play
journey
overcom
challeng
pose
infecti
agent
